Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Using AI Disagreement to Expose Gaps in Coverage Rules.

JAMA·2026

Same author

Phenotypic prediction of missense variants via deep contrastive learning.

Nature biomedical engineering·2026

Same author

Forecasting left ventricular systolic dysfunction in heart failure with artificial intelligence.

EClinicalMedicine·2026

Same author

Scaling medical AI across clinical contexts.

Nature medicine·2026

Same author

Heterogenous effect of automated alerts on mortality.

Journal of the American Medical Informatics Association : JAMIA·2025

Same author

The missing value of medical artificial intelligence.

Nature medicine·2025

Search research articles

Related Experiment Video

Updated: May 25, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

(Mis)treating the pharmacogenetic incidentalome.

Isaac S Kohane¹

¹Harvard Medical School Center for Biomedical Informatics, 10 Shattuck Street, Boston, Massachusetts 02115, USA. isaac_kohane@harvard.edu

Nature Reviews. Drug Discovery

|February 2, 2012

Summary

This summary is machine-generated.

Genome-wide screening aids personalized medicine by linking genetic variations to drug responses. Careful analysis is crucial to avoid overstating the impact of initial pharmacogenomic findings.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Experiment Videos

Last Updated: May 25, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Area of Science:

Genomics
Pharmacogenomics
Personalized Medicine

Background:

Genome-wide screening holds promise for advancing personalized medicine.
Identifying associations between genomic variants and drug responses is key.
Potential overstatement of pharmacogenomic findings could hinder progress.

Purpose of the Study:

To highlight the importance of rigorous validation in pharmacogenomic studies.
To ensure the reliable application of genomic insights in clinical practice.
To mitigate risks associated with premature conclusions from genome-wide association studies.

Main Methods:

Review of current methodologies in genome-wide screening.
Analysis of case studies demonstrating the impact of pharmacogenomic associations.
Discussion of strategies for validating and refining identified genomic-drug response links.

Main Results:

Initial genome-wide screens can identify numerous potential pharmacogenomic associations.
Subsequent validation studies are essential to confirm the clinical relevance and scope of these associations.
Failure to validate can lead to misapplication of genetic information in drug selection.

Conclusions:

Personalized medicine development relies on accurate and validated pharmacogenomic data.
Minimizing the impact of potentially narrow associations is critical for clinical utility.
Robust validation frameworks are necessary to translate genomic discoveries into effective patient care.